基于组织的基因组分析市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球基于组织的基因组分析市场预计将从 2025 年的 15.2 亿美元成长到 2031 年的 22.5 亿美元，复合年增长率达到 6.76%。

该市场由用于检测肿瘤组织样本以识别特定基因组变化（例如突变和拷贝数变异）的诊断技术组成，这些变化对于选择标靶治疗至关重要。该市场的主要驱动力是全球癌症发病率的不断上升，这显着增加了对精准分子表征的需求，从而支持个人化医疗。此外，伴随诊断的监管核准不断增加以及基因组数据在临床治疗方案中整合程度的提高也推动了该市场的发展。美国癌症协会预测，到2024年，美国新增癌症病例数将首次超过200万，凸显了精准诊断工具的紧迫感。

儘管成长势头强劲，但由于全面基因组检测高成本以及不同医疗体系报销政策不一致，该市场仍面临许多挑战。这些经济限制阻碍了患者获得检测的机会，并延缓了这些诊断测试在当地癌症诊疗机构的常规应用。此外，依赖侵入性切片检查来确保获得充足、高品质的组织样本也带来了后勤方面的挑战，因为样本数量或品质不足会导致检测失败，因此无法成功完成基因组分析。

市场驱动因素

次世代定序(NGS) 技术的快速发展显着提升了肿瘤分析的通量、准确性和成本效益，成为全球组织基因组分析市场发展的根本驱动力。从单基因检测到全面基因组分析 (CGP) 的转变主要得益于高通量定序平台的应用，这些平台使实验室能够有效处理大量的组织数据。这项技术进步使临床医生能够检测到传统方法无法识别的复杂标记，例如罕见突变和肿瘤突变负荷 (TMB)。这些先进工具在业界的快速普及显而易见；例如，Illumina 在其 2024 年 2 月的财报中宣布，其在 2023 财年共交付了 352 台 NovaSeq X 仪器，这表明全球基因组实验室正处于强劲的设备更新周期。

此外，随着治疗成功越来越依赖特定的分子诊断，精准医疗的日益普及和以生物标记为导向的药物开发平臺的成长正显着推动市场需求。生物製药公司正优先开发需要伴随诊断来识别合适患者的标靶治疗，从而将基因组分析整合到标准临床工作流程中。这一趋势在监管成果中也得到了体现。 2024年2月，个人化医疗联盟（PMC）宣布，2023年核准的新药中将有超过三分之一是个人化药物，这已是连续第四年实现这一目标。对生物标记指导治疗的依赖直接推动了诊断服务提供者的商业性成长。 Exact Sciences公司的案例便是一个例证，该公司报告称，其精准肿瘤学部门在上年度的收入达到6.29亿美元，凸显了基于组织的基因组检测在现代癌症治疗中的重要经济作用。

市场挑战

全球组织基因组分析市场的扩张受到全面基因组检测高成本和不一致的报销政策的显着阻碍。当保险公司拒绝承保或提供的报销金额不足以涵盖进行这些复杂检测的营运成本时，临床检查室常常面临沉重的经济负担。这种经济上的不确定性使得地方癌症中心无法常规进行广泛的基因组分析，导致市场准入仅限于资金雄厚的学术机构。因此，检测量持续低于临床需求，直接抑制了产生收入，并减缓了精准医疗工具的整体应用。

这种财务不稳定也严重影响了诊断服务提供者的营运能力，迫使他们在资源分配上做出艰难的抉择。根据美国病理学家协会 (CAP) 2024 年的数据，在过去五年中，72% 的病理诊所主任都受到了报销率下降的负面影响。这些财务限制迫使实验室减少人员配备和检测项目，导致检测结果返回延迟和服务能力下降。这些由支付机制不完全造成的营运瓶颈，阻碍了市场有效扩张以应对日益严重的全球癌症负担。

市场趋势

全球基于组织的基因组分析市场正因人工智慧 (AI) 与基因组数据解读的融合而发生变革，AI 的运用实现了对大规模次世代定序(NGS) 资料集的自动化分析。实验室正利用 AI 演算法加速变异註释，并检测出人工分析可能遗漏的可操作生物标记。这种技术融合正在推动精准肿瘤学的快速发展，而数据驱动的临床决策支援对于应对复杂全面的基因组分析至关重要。为了反映这一日益增长的需求，Tempus AI 在 2024 年 5 月的註册声明中公布，其 2023 财年的收入为 5.32 亿美元（同比增长 66%），凸显了市场对 AI 驱动的精准医疗解决方案的日益增长的需求。

同时，结合DNA和RNA分析的多组体学分析技术的兴起，使得人们能够全面了解肿瘤微环境。这一趋势超越了简单的突变检测，涵盖了基因表现，从而更深入地揭示了肿瘤异质性和治疗抗药性机制。研究人员和临床医生正在利用这些先进工具来优化免疫疗法的患者分层，推动了对太空生物学技术的显着投资。这项转变也得到了显着的财务成长的支持：2024年2月，10x Genomics宣布全年营收达6.187亿美元（年成长20%），这主要得益于太空分析和单细胞分析仪器的应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球基于组织的基因组分析市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过技术（定序技术、免疫组织化学等）
  • 依应用领域（个人化医疗、肿瘤诊断、研究）
  • 按最终用户（研究机构、临床研究机构、医院和诊所、诊断检查室、製药和生物技术公司、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美组织基因组分析市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲组织基因组分析市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区基于组织的基因组分析市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲基于组织的基因组分析市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美组织基因组分析市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球组织基因组分析市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Foundation Medicine Inc
• Illumina, Inc.
• QIAGEN NV
• Roche Diagnostics Corp
• Thermo Fisher Scientific Inc.
• Exact Sciences Corp
• Personal Genome Diagnostics Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Tissue Based Genomic Profiling Market is projected to expand from USD 1.52 Billion in 2025 to USD 2.25 Billion by 2031, achieving a CAGR of 6.76%. This market consists of diagnostic technologies that examine tumor tissue samples to identify specific genomic changes, such as mutations and copy number variations, which are essential for selecting targeted therapies. A key factor driving this market is the rising global incidence of cancer, which creates a critical need for precise molecular characterization to support personalized medicine. Furthermore, the market is bolstered by the increasing regulatory approvals for companion diagnostics and the incorporation of genomic data into clinical treatment planning. Highlighting the urgency for accurate diagnostic tools, the American Cancer Society projected in 2024 that new cancer cases in the United States would surpass 2 million for the first time.

Despite this positive growth trajectory, the market faces significant obstacles due to the high costs of comprehensive genomic testing and the lack of consistent reimbursement policies across various healthcare systems. These financial limitations often restrict patient access and slow the routine implementation of these diagnostic tests within community oncology practices. Additionally, the dependence on invasive biopsies to secure adequate high-quality tissue samples poses a logistical challenge, as insufficient sample quantity or quality can result in test failure and prevent the successful completion of genomic assays.

Market Driver

Rapid progress in Next-Generation Sequencing (NGS) technologies serves as a foundational driver for the Global Tissue Based Genomic Profiling Market, improving the throughput, accuracy, and cost-efficiency of tumor analysis. The transition from single-gene testing to comprehensive genomic profiling (CGP) is primarily powered by the adoption of high-capacity sequencing platforms that enable laboratories to process large volumes of tissue data effectively. This technological advancement allows clinicians to detect rare mutations and complex markers, such as Tumor Mutational Burden (TMB), which were previously unidentifiable using standard methods. The industry's rapid uptake of these advanced tools is evident; for instance, Illumina reported in its February 2024 financial results that it shipped 352 NovaSeq X instruments during the fiscal year 2023, indicating a strong equipment upgrade cycle in genomic labs worldwide.

Moreover, the increasing adoption of precision medicine and the growth of biomarker-focused drug development pipelines significantly boost market demand, as therapeutic success increasingly relies on specific molecular diagnoses. Biopharmaceutical companies are prioritizing the creation of targeted therapies that require companion diagnostics to identify suitable patients, thereby integrating genomic profiling into standard clinical workflows. This trend is highlighted by regulatory achievements; the Personalized Medicine Coalition noted in February 2024 that personalized medicines represented over one-third of all new drug approvals in 2023 for the fourth consecutive year. This dependence on biomarker-guided treatment directly fuels commercial growth for diagnostic providers, as demonstrated by Exact Sciences, which reported $629 million in revenue from its Precision Oncology segment in 2024 for the prior year, underscoring the vital economic role of tissue-based genomic testing in modern cancer care.

Market Challenge

The expansion of the Global Tissue Based Genomic Profiling Market is significantly hindered by the substantial costs associated with comprehensive genomic testing combined with inconsistent reimbursement policies. Clinical laboratories frequently encounter severe financial strain when insurance providers deny coverage or offer reimbursement rates that do not cover the operational expenses of performing these complex assays. This financial uncertainty discourages community oncology practices from routinely ordering broad genomic profiles, effectively restricting market access to well-funded academic centers. Consequently, the volume of tests conducted remains lower than clinical demand, which directly suppresses revenue generation and slows the overall adoption of precision medicine tools.

This financial instability also severely impacts the operational capabilities of diagnostic providers, necessitating difficult decisions regarding resource allocation. Data from the College of American Pathologists in 2024 revealed that 72% of pathology practice leaders experienced negative impacts from declining reimbursement rates over the previous five years. Such fiscal constraints force laboratories to reduce staffing or curtail their test menus, leading to slower turnaround times and diminished service availability. These operational bottlenecks, driven by inadequate payment mechanisms, prevent the market from scaling efficiently to meet the rising global burden of cancer.

Market Trends

The Global Tissue Based Genomic Profiling Market is being transformed by the integration of Artificial Intelligence (AI) for genomic data interpretation, which automates the analysis of extensive NGS datasets. Laboratories are increasingly utilizing AI algorithms to speed up variant annotation and detect actionable biomarkers that manual analysis might miss. This technological convergence facilitates the rapid scaling of precision oncology, making data-driven clinical decision support essential for managing the complexity of comprehensive profiles. Reflecting this growing demand, Tempus AI reported in its May 2024 registration statement that it generated USD 532 million in revenue for the fiscal year 2023, a 66% increase from the prior year, highlighting the appetite for AI-enabled precision medicine solutions.

Concurrently, the rise of multi-omics profiling, which combines DNA and RNA analysis, is providing a comprehensive view of the tumor microenvironment. This trend moves beyond simple mutation detection to include gene expression signatures, offering deeper insights into tumor heterogeneity and therapeutic resistance mechanisms. Researchers and clinicians are leveraging these advanced tools to refine patient stratification for immunotherapies, driving substantial investment in spatial biology technologies. This shift is confirmed by significant financial growth; 10x Genomics announced in February 2024 that its full-year revenue for 2023 reached USD 618.7 million, a 20% increase from 2022, fueled by the adoption of its spatial and single-cell profiling instruments.

Key Market Players

• Foundation Medicine Inc
• Illumina, Inc.
• QIAGEN N.V.
• Roche Diagnostics Corp
• Thermo Fisher Scientific Inc.
• Exact Sciences Corp
• Personal Genome Diagnostics Inc.

Report Scope

In this report, the Global Tissue Based Genomic Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Based Genomic Profiling Market, By Technology

• Sequencing Techniques
• Immunohistochemistry
• Others

Tissue Based Genomic Profiling Market, By Application

• Personalized Medicine
• Oncological Diagnostics
• Research

Tissue Based Genomic Profiling Market, By End-User

• Research Institutes
• Clinical Research Organizations
• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Others

Tissue Based Genomic Profiling Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue Based Genomic Profiling Market.

Available Customizations:

Global Tissue Based Genomic Profiling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Based Genomic Profiling Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Sequencing Techniques, Immunohistochemistry, Others)
  • 5.2.2. By Application (Personalized Medicine, Oncological Diagnostics, Research)
  • 5.2.3. By End-User (Research Institutes, Clinical Research Organizations, Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Tissue Based Genomic Profiling Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tissue Based Genomic Profiling Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Tissue Based Genomic Profiling Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Tissue Based Genomic Profiling Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User

7. Europe Tissue Based Genomic Profiling Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tissue Based Genomic Profiling Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Tissue Based Genomic Profiling Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Tissue Based Genomic Profiling Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Tissue Based Genomic Profiling Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Tissue Based Genomic Profiling Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. Asia Pacific Tissue Based Genomic Profiling Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tissue Based Genomic Profiling Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Tissue Based Genomic Profiling Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Tissue Based Genomic Profiling Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Tissue Based Genomic Profiling Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Tissue Based Genomic Profiling Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Tissue Based Genomic Profiling Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tissue Based Genomic Profiling Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Tissue Based Genomic Profiling Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Tissue Based Genomic Profiling Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. South America Tissue Based Genomic Profiling Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tissue Based Genomic Profiling Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Tissue Based Genomic Profiling Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Tissue Based Genomic Profiling Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tissue Based Genomic Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Foundation Medicine Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc.
• 15.3. QIAGEN N.V.
• 15.4. Roche Diagnostics Corp
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. Exact Sciences Corp
• 15.7. Personal Genome Diagnostics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer